Comparative Pharmacology
Head-to-head clinical analysis: PROVAL 3 versus TUZISTRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROVAL 3 versus TUZISTRA XR.
PROVAL #3 vs TUZISTRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
Tuzistra XR is a combination of codeine (an opioid agonist) and promethazine (a phenothiazine derivative with antihistaminic, sedative, and anticholinergic effects). Codeine binds to mu-opioid receptors in the CNS, inhibiting cough reflex. Promethazine acts as a histamine H1 receptor antagonist and may have additional central anticholinergic and sedative effects.
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
Initial: 25 mg orally twice daily; may increase to 50 mg twice daily after 1 week based on tolerability; maximum 50 mg twice daily.
None Documented
None Documented
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Terminal elimination half-life is 7 hours for the parent drug; clinically, this supports twice-daily dosing for sustained symptom relief.
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Primarily hepatic metabolism via glucuronidation; approximately 20% of the dose is excreted unchanged in urine, and 80% is eliminated as metabolites in feces via biliary excretion.
Category C
Category C
Antitussive
Antitussive/decongestant combination